CClinicalTrials.gg
TerminatedNCT03622840Updated Jun 20, 2019

Impact of Individual Cognitive Remediation for Parkinson's Disease

An interventional study of Cognitive Remediation in Cognitive Impairment and Parkinson Disease, sponsored by New York Institute of Technology. Terminated at 1 site in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-20.

Sponsored by New York Institute of Technology · Not applicable, Interventional, and Supportive care

Why this study was terminated
Completed
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This is an interventional clinical trial that will be conducted as a pilot project. Investigators hope to conduct the study to obtain at least 10 study completers.

The plan is to screen 20 Parkinson's Disease (PD) patients attending the Academic Health Care Center (AHCC) at NYIT College of Osteopathic Medicine clinic and enroll the eligible candidates based on the inclusion and exclusion criteria. Subjects will have 11 study visits over the 11-week period. Subjects cognition will be assessed using a paper-based Test of Memory and Learning (TOMAL) tool. The same tool will be used to asses and compare the cognition at baseline, and end study visits. The weekly 30-mins of cognitive remediation exercises will be done using the Brain. HQ cognitive remediation software.

02

Conditions studied

  • Cognitive Impairment
  • Parkinson Disease

Browse trials for

Keywords

  • Cognitive Remediation
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 12 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

New York Institute of Technology is the lead sponsor of 59 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Subjects must be between 40 and 75 years old (including both ages) at the time of study screening.
  2. Subjects must have a diagnosis of Parkinson's Disease by a physician.
  3. Subjects must demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in this research study.
  4. Subjects must have been clinically stable (non-acute) for 2 weeks prior to consent; in the judgment of the Investigator.
  5. Subjects with a cognition level between Impaired and Average (scaled score between 4-12 or Index Score between 70-110) based on TOMAL Cognitive assessment at Visit 1
  6. Subjects must have the visual, auditory, and motor capacity to use the intervention in the judgment of the Principal Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are participating in a concurrent research study or another interventional clinical trial 30 days prior to consenting.
  2. Subjects having a history of mental retardation or pervasive developmental disorder; or other co-morbid neurological disorder (e.g., epilepsy.)
  3. Subjects who appear to be intoxicated or under the influence of a controlled substance on any day of assessment must be rescheduled and may be discontinued based upon the discretion of the investigator
  4. Subjects on medications that affect the cognition in the last 12 hours prior to the study visits that assess the cognitive functions
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Other
    Parkinson's disease patients with cognitive impairment

    Online cognitive remediation program.

    Behavioral: Cognitive Remediation

Interventions

  • BehavioralCognitive Remediation

    Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks

    Also known as: Brain.HQ

06

What researchers measure

Primary outcomes

  1. Change of Test of Memory and Learning (TOMAL) score

    Paper based memory and attention test administered at the beginning and end of the study

    Time frame: Baseline and 11 weeks

07

Study locations

1 site
  • New York Institute of Technology College of Osteopathic Medicine
    Old Westbury, New York 11568, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03622840
Lead sponsor
New York Institute of Technology
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Jul 12, 2018
Primary completion
Oct 30, 2018
Completion
Oct 30, 2018
Last update
Jun 20, 2019

Study contacts

Anu Raj, Psy.D
principal investigator · New York Institute of Technology College of Osteopathic Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion